Search

Your search keyword '"Robins H"' showing total 998 results
Start Over Author "Robins H"
998 results on '"Robins H"'

201. Radiation Therapy

Author

Charkravarti, A., primary, Wang, M., additional, Robins, I., additional, Guha, A., additional, Curren, W., additional, Brachman, D., additional, Schultz, C., additional, Choucair, A., additional, Dolled-Filhart, M., additional, Christiansen, J., additional, Gustavson, M., additional, Molinaro, A., additional, Mischel, P., additional, Lautenschlaeger, T., additional, Dicker, A., additional, Mehta, M., additional, Phillips, C. A., additional, Dhulibala, S., additional, Hallahan, D., additional, Jaboin, J., additional, Cardinale, F. S., additional, Dickey, P., additional, Goodrich, I., additional, Gorelick, J., additional, Sinha, R., additional, Dest, V. M., additional, Chen, C., additional, Olsen, C., additional, Franklin, W., additional, Kleinschmidt-DeMasters, B., additional, Kavanagh, B. D., additional, Lillehei, K., additional, Waziri, A., additional, Damek, D., additional, Gaspar, L. E., additional, Stauder, M. C., additional, Laack, N. N., additional, Link, M. J., additional, Pollock, B. E., additional, Schomberg, P. J., additional, Fraser, J. F., additional, Pannullo, S. C., additional, Moliterno, J., additional, Cobb, W., additional, Stieg, P. E., additional, Vinchon-Petit, S., additional, Jarnet, D., additional, Michalak, S., additional, Lewis, A., additional, Benoit, J.-P., additional, Menei, P., additional, Desmarais, G., additional, Paquette, B., additional, Bujold, R., additional, Mathieu, D., additional, Fortin, D., additional, Cuneo, K. C., additional, Vredenburgh, J. J., additional, Sampson, J. H., additional, Reardon, D. A., additional, Desjardins, A., additional, Peters, K. L., additional, Kirkpatrick, J. P., additional, Patel, P. N., additional, Vyas, R., additional, Suryanarayan, U., additional, Bhavsar, D., additional, Hayhurst, C., additional, Monsalves, E., additional, Van Prooijen, M., additional, Menard, C., additional, Zadeh, G., additional, Chung, C., additional, Burrell, K., additional, Lindsey, P., additional, Burri, S. H., additional, Asher, A. L., additional, Kelly, R. B., additional, Boltes, P., additional, Fraser, R. W., additional, Dilmanian, F. A., additional, Rusek, A., additional, Desnoyers, N. R., additional, Park, J. Y., additional, Dane, B., additional, Dioszegi, I., additional, Hurley, S. D., additional, O'Banion, M. K., additional, Tomasi, D., additional, Wang, R., additional, Meek, A. G., additional, Sleire, L., additional, Wang, J., additional, Heggdal, J., additional, Pedersen, P.-H., additional, Enger, P. O., additional, Clump, D. A., additional, Srinivas, R., additional, Wegner, R. E., additional, Heron, D. E., additional, Burton, S. A., additional, Mintz, A. H., additional, Howard, S. P., additional, Robins, H. I., additional, Tome, W. A., additional, Paravati, A. J., additional, Gardner, P. A., additional, Snyderman, C., additional, Ozhasoglu, C., additional, Quinn, A., additional, Seelman, K., additional, Chang, J. H., additional, Park, Y. G., additional, Mehta, M. J., additional, Vyas, R. K., additional, Bhavsar, D. C., additional, Guarnaschelli, J. N., additional, Imwalle, L., additional, Ying, J., additional, McPherson, C., additional, Warnick, R., additional, Breneman, J., additional, Khwaja, S. S., additional, Wetjen, N. M., additional, Brown, P. D., additional, Siedow, M., additional, Nestler, U., additional, Perry, J., additional, Huebner, A., additional, Chakravarti, A., additional, Glass, J., additional, Andrews, D., additional, Werner-Wasik, M., additional, Evans, J., additional, Lawrence, R., additional, Martinez, N., additional, Anuradha, G., additional, David, M., additional, Sara, M., additional, Mark, L., additional, Ricardo, B., additional, Jeff, J., additional, Juan, H., additional, Kozono, D., additional, Zinn, P., additional, Ng, K., additional, Melian, E., additional, Prabhu, V., additional, Sethi, A., additional, Barton, K., additional, Anderson, D., additional, Rockne, R. C., additional, Mrugala, M., additional, Rockhill, J., additional, and Swanson, K. R., additional

Published
2010
Full Text
View/download PDF

202. ACR Appropriateness Criteria®: Single Brain Metastasis

Author

Suh, John H., primary, Videtic, Gregory M.M., additional, Aref, Amr M., additional, Germano, Isabelle, additional, Goldsmith, Brian J., additional, Imperato, Joseph P., additional, Marcus, Karen J., additional, McDermott, Michael W., additional, McDonald, Mark W., additional, Patchell, Roy A., additional, Robins, H. Ian, additional, Rogers, C. Leland, additional, Wolfson, Aaron H., additional, Wippold, Franz J., additional, and Gaspar, Laurie E., additional

Published
2010
Full Text
View/download PDF

203. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)

Author

Iwamoto, F. M., primary, Lamborn, K. R., additional, Robins, H. I., additional, Mehta, M. P., additional, Chang, S. M., additional, Butowski, N. A., additional, DeAngelis, L. M., additional, Abrey, L. E., additional, Zhang, W.-T., additional, Prados, M. D., additional, and Fine, H. A., additional

Published
2010
Full Text
View/download PDF

204. EGFR Signaling Through an Akt-SREBP-1–Dependent, Rapamycin-Resistant Pathway Sensitizes Glioblastomas to Antilipogenic Therapy

Author

Guo, Deliang, primary, Prins, Robert M., additional, Dang, Julie, additional, Kuga, Daisuke, additional, Iwanami, Akio, additional, Soto, Horacio, additional, Lin, Kelly Y., additional, Huang, Tiffany T., additional, Akhavan, David, additional, Hock, M. Benjamin, additional, Zhu, Shaojun, additional, Kofman, Ava A., additional, Bensinger, Steve J., additional, Yong, William H., additional, Vinters, Harry V., additional, Horvath, Steve, additional, Watson, Andrew D., additional, Kuhn, John G., additional, Robins, H. Ian, additional, Mehta, Minesh P., additional, Wen, Patrick Y., additional, DeAngelis, Lisa M., additional, Prados, Michael D., additional, Mellinghoff, Ingo K., additional, Cloughesy, Timothy F., additional, and Mischel, Paul S., additional

Published
2009
Full Text
View/download PDF

205. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)

Author

Wen, Patrick Y., primary, Yung, W.K. Alfred, additional, Lamborn, Kathleen R., additional, Norden, Andrew D., additional, Cloughesy, Timothy F., additional, Abrey, Lauren E., additional, Fine, Howard A., additional, Chang, Susan M., additional, Robins, H. Ian, additional, Fink, Karen, additional, DeAngelis, Lisa M., additional, Mehta, Minesh, additional, Di Tomaso, Emmanuelle, additional, Drappatz, Jan, additional, Kesari, Santosh, additional, Ligon, Keith L., additional, Aldape, Ken, additional, Jain, Rakesh K., additional, Stiles, Charles D., additional, Egorin, Merrill J., additional, and Prados, Michael D., additional

Published
2009
Full Text
View/download PDF

206. American College of Radiology Appropriateness Criteria on Multiple Brain Metastases

Author

Videtic, Gregory M.M., primary, Gaspar, Laurie E., additional, Aref, Amr M., additional, Germano, Isabelle M., additional, Goldsmith, Brian J., additional, Imperato, Joseph P., additional, Marcus, Karen J., additional, McDermott, Michael W., additional, McDonald, Mark W., additional, Patchell, Roy A., additional, Robins, H. Ian, additional, Rogers, C. Leland, additional, Suh, John H., additional, Wolfson, Aaron H., additional, and Wippold, Franz J., additional

Published
2009
Full Text
View/download PDF

208. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma

Author

Norden, Andrew D., primary, Raizer, Jeffrey J., additional, Abrey, Lauren E., additional, Lamborn, Kathleen R., additional, Lassman, Andrew B., additional, Chang, Susan M., additional, Yung, W. K. Alfred, additional, Gilbert, Mark R., additional, Fine, Howard A., additional, Mehta, Minesh, additional, DeAngelis, Lisa M., additional, Cloughesy, Timothy F., additional, Robins, H. Ian, additional, Aldape, Kenneth, additional, Dancey, Janet, additional, Prados, Michael D., additional, Lieberman, Frank, additional, and Wen, Patrick Y., additional

Published
2009
Full Text
View/download PDF

211. 'Eight-drugs-in-one-day' chemotherapy administered before and after radiotherapy to adult patients with malignant gliomas

Author

Rozental, Jack M., Robins, H. Ian, Finlay, Jonathan, Healey, Barbara, Levin, Allan B., Steeves, Richard A., Kohler, Peter C., Schutta, Henry S., and Trump, Donald L.

Subjects
Chemotherapy -- Research, Astrocytoma, Brain cancer, Health
Abstract

Patients with malignant astrocytomas, i.e. glioblastoma multiforme and anaplastic astrocytoma (cancers involving nerve cells), have a median survival time that rarely surpasses 50 weeks. The standard treatment, which consists of radiotherapy and carmustine (BCNU), provides survival rates of about 30 percent at 18 months; this is the standard against which many experimental protocols are measured. Preliminary work in children with malignant gliomas and medulloblastomas has suggested some benefits may be derived from a chemotherapeutic program consisting of eight drugs. To determine if a similar program might be beneficial for adults, 31 previously untreated patients were placed on an 'eight-drugs-in-one-day' chemotherapeutic program. The patients were given methylprednisolone, vincristine, lomustine, procarbazine, hydroxyurea, cytosine arabinoside, dacarbazine, and cisplatin over an intricate 18-hour schedule. The chemotherapy began no more than two weeks after the surgery which histologically confirmed the malignant glioma. Patients received two cycles of chemotherapy prior to radiotherapy, and eight additional cycles were planned. Most patients received fewer than eight cycles due to tumor progression and treatment toxicity. Bone-marrow suppression was common; 16 patients developed infections requiring treatment; two of these infections were life-threatening. Four patients developed neuropathy (nerve disease), and five developed thrombophlebitis (inflammation and blockage of a vein). The survival rate was similar to other chemotherapeutic protocols. Because other protocols are less toxic, it was concluded that the 'eight-drugs-in-one-day' regimen offers no benefit to these patients. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1989

213. A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas

Author

Butowski, Nicholas, primary, Lamborn, Kathleen R., additional, Lee, Bee L., additional, Prados, Michael D., additional, Cloughesy, Timothy, additional, DeAngelis, Lisa M., additional, Abrey, Lauren, additional, Fink, Karen, additional, Lieberman, Frank, additional, Mehta, Minesh, additional, Ian Robins, H., additional, Junck, Larry, additional, Salazar, Andres M., additional, and Chang, Susan M., additional

Published
2008
Full Text
View/download PDF

214. Neurooncology clinical trial design for targeted therapies: Lessons learned from the North American Brain Tumor Consortium

Author

Chang, Susan M., primary, Lamborn, Kathleen R., additional, Kuhn, John G., additional, Yung, W.K. Alfred, additional, Gilbert, Mark R., additional, Wen, Patrick Y., additional, Fine, Howard A., additional, Mehta, Minesh P., additional, DeAngelis, Lisa M., additional, Lieberman, Frank S., additional, Cloughesy, Timothy F., additional, Robins, H. Ian, additional, Abrey, Lauren E., additional, and Prados, Michael D., additional

Published
2008
Full Text
View/download PDF

216. Prospective Evaluation of Quality of Life and Neurocognitive Effects in Patients With Multiple Brain Metastases Receiving Whole-Brain Radiotherapy With or Without Thalidomide on Radiation Therapy Oncology Group (RTOG) Trial 0118

Author

Corn, Benjamin W., primary, Moughan, Jennifer, additional, Knisely, Jonathan P.S., additional, Fox, Sherry W., additional, Chakravarti, Arnab, additional, Yung, W.K. Alfred, additional, Curran, Walter J., additional, Robins, H. Ian, additional, Brachman, David G., additional, Henderson, Randal H., additional, Mehta, Minesh P., additional, and Movsas, Benjamin, additional

Published
2008
Full Text
View/download PDF

217. A Phase III Study of Conventional Radiation Therapy Plus Thalidomide Versus Conventional Radiation Therapy for Multiple Brain Metastases (RTOG 0118)

Author

Knisely, Jonathan P.S., primary, Berkey, Brian, additional, Chakravarti, Arnab, additional, Yung, Al W.K., additional, Curran, Walter J., additional, Robins, H. Ian, additional, Movsas, Benjamin, additional, Brachman, David G., additional, Henderson, Randall H., additional, and Mehta, Minesh P., additional

Published
2008
Full Text
View/download PDF

219. Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas

Author

Lamborn, Kathleen R., primary, Yung, W. K. Alfred, additional, Chang, Susan M., additional, Wen, Patrick Y., additional, Cloughesy, Timothy F., additional, DeAngelis, Lisa M., additional, Robins, H. Ian, additional, Lieberman, Frank S., additional, Fine, Howard A., additional, Fink, Karen L., additional, Junck, Larry, additional, Abrey, Lauren, additional, Gilbert, Mark R., additional, Mehta, Minesh, additional, Kuhn, John G., additional, Aldape, Kenneth D., additional, Hibberts, Janelle, additional, Peterson, Pamela M., additional, and Prados, Michael D., additional

Published
2008
Full Text
View/download PDF

221. Isometries in anti-de Sitter and Conformal Superspaces

Author

Claus, P., Rahmfeld, J., Robins, H., Tannenhauser, J., Zunger, Y., Claus, P., Rahmfeld, J., Robins, H., Tannenhauser, J., and Zunger, Y.

Abstract

We derive explicit forms for the superisometries of a wide class of supercoset manifolds, including those with fermionic generators in the stability group. We apply the results to construct the action of SU(2,2|4) on three supercoset manifolds: (10|32)-dimensional AdS_5 x S^5 superspace, (4|16)-dimensional conformal superspace, and a novel (10|16)-dimensional conformal superspace. Using superembedding techniques, we show, to lowest non-trivial order in the fermions, that at the boundary of AdS_5, the superisometries of the AdS_5 x S^5$ superspace reduce to the standard N=4 superconformal transformations. In particular, half of the 32 fermionic coordinates decouple from the superisometries., Comment: 19 pages, LaTeX

Published
2000
Full Text
View/download PDF

222. 3:30 PM, Abstract No. 286 - FEATURED ABSTRACT, Tumor and systemic immune responses to pre-operative cryoablation plus immune therapy with ipilimumab in early stage breast cancer

Author

Page, D., Yuan, J., Dong, Z., Ginsberg, A.A., Wong, P., Emerson, R., Sung, J., Comstock, C., Mu, Z., Solomon, S.B., Diab, A., Durack, J.C., Maybody, M., Erinjeri, J.P., Brogi, E., Morris, E., Patil, S., Robins, H., Wolchok, J., Hudis, C., Norton, L., Allison, J., and McArthur, H.

Published
2015
Full Text
View/download PDF

227. A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study.

Author

Robins, H., Zhang, Peixin, Gilbert, Mark, Chakravarti, Arnab, Groot, John, Grimm, Sean, Wang, Fen, Lieberman, Frank, Krauze, Andra, Trotti, Andy, Mohile, Nimish, Kee, Andrew, Colman, Howard, Cavaliere, Robert, Kesari, Santosh, Chmura, Steven, and Mehta, Minesh

Abstract

This study tested the hypothesis that ABT-888 (velparib), a poly (ADP-ribose) polymerase (PARP) inhibitor, can modulate temozolomide (TMZ) resistance in recurrent TMZ refractory glioblastoma patients. The combination regimen (TMZ/ABT-888) was tested using two randomized schedules (5 vs. 21 days), with 6-month progression free survival (PFS6) as the primary endpoint. The maximum tolerated dose (MTD) for TMZ using the 21 day of 28 TMZ schedule, in concert with 40 mg BID ABT-888 was determined in a phase I portion of this study, and previously reported to be 75 mg/m (arm1). The MTD for ABT-888 (40 mg BID) and the 5 of 28 day TMZ (150-200 mg/m) schedule was known from prior trials (arm2). Two cohorts were studied: bevacizumab (BEV) naïve (n = 151), and BEV refractory (n = 74). Overall ten patients were ineligible. The incidence rate of grade 3/4 myelosuppression over all was 20.0 %. For the BEV refractory cohort, the PFS 6 was 4.4 %; for the BEV naïve cohort, PFS6 was 17 %. Overall survival was similar for both arms in both the BEV naïve [median survival time (MST) 10.3 M; 95 % CI 8.4-12] and BEV refractory cohort (MST 4.7 M; 95 %CI 3.5-5.6). The median PFS was essentially the same for both arms and both cohorts at ~2.0 M (95 % CI 1.9-2.1). [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

232. Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancer.

Author

Nayak, Lakshmi, DeAngelis, Lisa M., Robins, H. Ian, Govindan, Ramaswamy, Gadgeel, Shirish, Kelly, Karen, Rigas, James R., Peereboom, David M., Rosenfeld, Steven S., Muzikansky, Alona, Zheng, Ming, Urban, Patrick, Abrey, Lauren E., Omuro, Antonio, and Wen, Patrick Y.

Subjects
NON-small-cell lung carcinoma, CANCER treatment, BRAIN metastasis, DISEASE relapse, BLOOD-brain barrier, MEDICATION safety, PHARMACOKINETICS, PATIENTS, THERAPEUTICS, ANTINEOPLASTIC agents, BRAIN tumors, CANCER relapse, CLINICAL trials, COMPARATIVE studies, DRUG administration, INTRAVENOUS therapy, LONGITUDINAL method, LUNG cancer, LUNG tumors, MACROLIDE antibiotics, RESEARCH methodology, MEDICAL cooperation, RESEARCH, RESEARCH funding, SURVIVAL analysis (Biometry), EVALUATION research, TREATMENT effectiveness, DISEASE progression
Abstract

Background: Treatment options for patients with non-small cell lung cancer (NSCLC) with brain metastases are limited. Patupilone (EPO906), a blood-brain barrier-penetrating, microtubule-targeting, cytotoxic agent, has shown clinical activity in phase 1/2 studies in patients with NSCLC. This study evaluates the efficacy, pharmacokinetics, and safety of patupilone in NSCLC brain metastases.Methods: Adult patients with NSCLC and confirmed progressive brain metastases received patupilone intravenously at 10 mg/m(2) every 3 weeks. The primary endpoint of this multinomial 2-stage study combined early progression (EP; death or progression within 3 weeks) and progression-free survival at 9 weeks (PFS9w) to determine drug activity.Results: Fifty patients with a median age of 60 years (range, 33-74 years) were enrolled; the majority were men (58%), and most had received prior therapy for brain metastases (98%). The PFS9w rate was 36%, and the EP rate was 26%. Patupilone blood pharmacokinetic analyses showed mean areas under the concentration-time curve from time zero to 504 hours for cycles 1 and 3 of 1544 and 1978 ng h/mL, respectively, and a mean steady state distribution volume of 755 L/m(2) . Grade 3/4 adverse events (AEs), regardless of their relation with the study drug, included diarrhea (24%), pulmonary embolisms (8%), convulsions (4%), and peripheral neuropathy (4%). All patients discontinued the study drug: 31 (62%) for disease progression and 13 (26%) for AEs. Twenty-five of 32 deaths were due to brain metastases. The median time to progression and the overall survival were 3.2 and 8.8 months, respectively.Conclusions: This is the first prospective study of chemotherapy for recurrent brain metastases from NSCLC. In this population, patupilone demonstrated activity in heavily treated patients. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

233. Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study.

Author

Mehta, Minesh, Wang, Ding, Wang, Fen, Kleinberg, Lawrence, Brade, Anthony, Robins, H., Turaka, Aruna, Leahy, Terri, Medina, Diane, Xiong, Hao, Mostafa, Nael, Dunbar, Martin, Zhu, Ming, Qian, Jane, Holen, Kyle, Giranda, Vincent, and Curran, Walter

Abstract

Veliparib, a potent, oral PARP inhibitor, potentiates the antitumor activity of radiation therapy and crosses the blood-brain barrier. This was a phase 1 dose-escalation study evaluating the safety, and secondarily the antitumor activity of veliparib in combination with whole brain radiation therapy (WBRT) in patients with brain metastases, in order to power future trials. Patients with brain metastases from primary solid tumors were treated with WBRT (30.0 or 37.5 Gy in 10 or 15 fractions) and veliparib (escalating doses of 10-300 mg, orally BID). Safety and tumor response were assessed. Observed survival was compared to predicted survival based on a published nomogram. Eighty-one patients (median age 58 years) were treated. The most common primary tumor types were non-small cell lung (NSCLC; n = 34) and breast cancer (n = 25). The most common AEs deemed possibly related to veliparib (AEs, ≥15 %) were fatigue (30 %), nausea (22 %), and decreased appetite (15 %). Fatigue (5 %), hypokalemia and hyponatremia (3 % each) were the only Grade 3/4 AEs deemed possibly related to veliparib observed in ≥2 patients. Although this was an uncontrolled study, preliminary efficacy results were better than predicted: the median survival time (MST, 95 % CI) for the NSCLC subgroup was 10.0 mo (3.9-13.5) and for the breast cancer subgroup was 7.7 mo (2.8-15.0) compared to a nomogram-model-predicted MST of 3.5 mo (3.3-3.8) and 4.9 mo (4.2-5.5). The addition of veliparib to WBRT did not identify new toxicities when compared to WBRT alone. Based on encouraging safety and preliminary efficacy results, a randomized, controlled phase 2b study is ongoing. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

236. Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08

Author

Wen, Patrick Y., primary, Yung, W.K. Alfred, additional, Lamborn, Kathleen R., additional, Dahia, Patricia L., additional, Wang, Yanfeng, additional, Peng, Bin, additional, Abrey, Lauren E., additional, Raizer, Jeffrey, additional, Cloughesy, Timothy F., additional, Fink, Karen, additional, Gilbert, Mark, additional, Chang, Susan, additional, Junck, Larry, additional, Schiff, David, additional, Lieberman, Frank, additional, Fine, Howard A., additional, Mehta, Minesh, additional, Robins, H. Ian, additional, DeAngelis, Lisa M., additional, Groves, Morris D., additional, Puduvalli, Vinay K., additional, Levin, Victor, additional, Conrad, Charles, additional, Maher, Elizabeth A., additional, Aldape, Kenneth, additional, Hayes, Michael, additional, Letvak, Laurie, additional, Egorin, Merrill J., additional, Capdeville, Renaud, additional, Kaplan, Richard, additional, Murgo, Anthony J., additional, Stiles, Charles, additional, and Prados, Michael D., additional

Published
2006
Full Text
View/download PDF

237. Phase II Trial of Tipifarnib in Patients With Recurrent Malignant Glioma Either Receiving or Not Receiving Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study

Author

Cloughesy, Timothy F., primary, Wen, Patrick Y., additional, Robins, H. Ian, additional, Chang, Susan M., additional, Groves, Morris D., additional, Fink, Karen L., additional, Junck, Larry, additional, Schiff, David, additional, Abrey, Lauren, additional, Gilbert, Mark R., additional, Lieberman, Frank, additional, Kuhn, John, additional, DeAngelis, Lisa M., additional, Mehta, Minesh, additional, Raizer, Jeff J., additional, Yung, W.K. Alfred, additional, Aldape, Ken, additional, Wright, John, additional, Lamborn, Kathleen R., additional, and Prados, Michael D., additional

Published
2006
Full Text
View/download PDF

239. Prospective neurocognitive effects and quality of life (QOL) in patients with multiple brain metastases receiving whole brain radiation (WBRT) ± thalidomide on radiation therapy oncology group (RTOG) trial 0118

Author

Fox, S., primary, Berkey, B., additional, Knisely, J., additional, Chakravarti, A., additional, Yung, W. A., additional, Curran, W., additional, Robins, H., additional, Brachmen, D., additional, Henderson, R., additional, Mehta, M., additional, and Movas, B., additional

Published
2006
Full Text
View/download PDF

240. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study1

Author

Prados, Michael D., primary, Lamborn, Kathleen, additional, Yung, W.K.A., additional, Jaeckle, Kurt, additional, Robins, H. Ian, additional, Mehta, Minesh, additional, Fine, Howard A., additional, Wen, Patrick Y., additional, Cloughesy, Timothy, additional, Chang, Susan, additional, Nicholas, M. Kelly, additional, Schiff, David, additional, Greenberg, Harry, additional, Junck, Larry, additional, Fink, Karen, additional, Hess, Ken, additional, and Kuhn, John, additional

Published
2006
Full Text
View/download PDF

242. Phase I Trial of Tipifarnib in Patients With Recurrent Malignant Glioma Taking Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study

Author

Cloughesy, Timothy F., primary, Kuhn, John, additional, Robins, H. Ian, additional, Abrey, Lauren, additional, Wen, Patrick, additional, Fink, Karen, additional, Lieberman, Frank S., additional, Mehta, Minesh, additional, Chang, Susan, additional, Yung, Alfred, additional, DeAngelis, Lisa, additional, Schiff, David, additional, Junck, Larry, additional, Groves, Morris, additional, Paquette, Steve, additional, Wright, John, additional, Lamborn, Kathleen, additional, Sebti, Said M., additional, and Prados, Michael, additional

Published
2005
Full Text
View/download PDF

244. Single-Nucleotide Polymorphisms in the p53 Pathway

Author

HARRIS, S.L., primary, GIL, G., additional, HU, W., additional, ROBINS, H., additional, BOND, E., additional, HIRSHFIELD, K., additional, FENG, Z., additional, YU, X., additional, TERESKY, A.K., additional, BOND, G., additional, and LEVINE, A.J., additional

Published
2005
Full Text
View/download PDF

245. Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs

Author

Chang, Susan M., primary, Kuhn, John, additional, Wen, Patrick, additional, Greenberg, Harry, additional, Schiff, David, additional, Conrad, Charles, additional, Fink, Karen, additional, Robins, H. Ian, additional, Cloughesy, Timothy, additional, De Angelis, Lisa, additional, Razier, Jeffrey, additional, Hess, Kenneth, additional, Dancey, Janet, additional, and Prados, Michael D., additional

Published
2004
Full Text
View/download PDF

248. Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study

Author

Prados, Michael D., primary, Yung, W.K. Alfred, additional, Fine, Howard A., additional, Greenberg, Harry S., additional, Junck, Larry, additional, Chang, Susan M., additional, Nicholas, M. Kelly, additional, Robins, H. Ian, additional, Mehta, Minesh P., additional, Fink, Karen L., additional, Jaeckle, Kurt A., additional, Kuhn, John, additional, Hess, Kenneth R., additional, and Schold, S. Clifford, additional

Published
2004
Full Text
View/download PDF

250. Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma

Author

Chang, Susan M., primary, Prados, Michael D., additional, Yung, W. K. Alfred, additional, Fine, Howard, additional, Junck, Larry, additional, Greenberg, Harry, additional, Robins, H. Ian, additional, Mehta, Minesh, additional, Fink, Karen L., additional, Jaeckle, Kurt A., additional, Kuhn, John, additional, Hess, Kenneth, additional, and Schold, Clifford, additional

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results